Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Meta-Analysis
. 2017 Mar 14;23(10):1909-1919.
doi: 10.3748/wjg.v23.i10.1909.

Markers of systemic inflammation and colorectal adenoma risk: Meta-analysis of observational studies

Justyna Godos  1 , Antonio Biondi  1 , Fabio Galvano  1 , Francesco Basile  1 , Salvatore Sciacca  1 , Edward L Giovannucci  1 , Giuseppe Grosso  1
Affiliations
Meta-Analysis

Markers of systemic inflammation and colorectal adenoma risk: Meta-analysis of observational studies

Justyna Godos et al. World J Gastroenterol. .

Abstract

Aim: To perform a meta-analysis of observational studies on inflammatory markers levels and occurrence of colorectal adenoma.

Methods: PubMed and EMBASE databases were searched until March 2016 for the articles reporting on the circulating levels of inflammatory markers, including: C-reactive protein (CRP), interleukin-6 (IL-6), and tumor necrosis factor-alpha (TNF-α) and risk of colorectal adenoma. Random-effects models were used to calculate summary odds ratios (ORs) with 95%CIs for the highest vs lowest category of exposure. Heterogeneity was assessed by using the Q test and I2 statistic. Subgroup analyses were also performed to test for potential source of heterogeneity.

Results: A total of 14 case-control studies were included. Ten studies on CRP including a total of 3350 cases and 4168 controls showed non-significant summary (OR = 1.23, 95%CI: 0.98-1.54; I2 = 54%, Pheterogeneity = 0.01) in the general analysis, but significant increased odds when considering only advanced adenoma (OR = 1.59, 95%CI: 1.09-2.32; I2 = 44%, Pheterogeneity = 0.15). Subgroup and stratified analyses revealed a potential influence of smoking status and aspirin use on the association between CRP levels and colorectal adenoma. Five studies examined the association between circulating levels of TNF-α and colorectal adenoma risk, including a total of 1,568 cases and 2,832 controls. The summary OR for the highest vs the lowest category of exposure was 1.00 (95%CI: 0.77-1.29). The relationship between circulating IL-6 levels and colorectal adenoma risk was investigated in 7 studies including a total of 1936 cases and 3611 controls. The summary OR for the highest vs the lowest category of exposure was 1.19 (95%CI: 0.92-1.55).

Conclusion: Summary of current evidence suggests a positive association of CRP levels and advanced colorectal adenoma risk. The role of potential confounding factors should be further evaluated.

Keywords: C-reactive protein; Colorectal adenoma; Inflammatory markers; Interleukin-6; Meta-analysis; Tumor necrosis factor-alpha.

PubMed Disclaimer

Conflict of interest statement

Conflict-of-interest statement: The authors deny any conflict of interest.

Figures

Figure 1
Figure 1
Study selection process. CRP: C-reactive protein; IL-6: Interleukin-6; TNF-α: Tumor necrosis factor-alpha.
Figure 2
Figure 2
Meta-analysis of highest vs lowest category of C-reactive protein and risk of colorectal adenoma, total and by advancement status. CRP: C-reactive protein.
Figure 3
Figure 3
Meta-analysis of highest vs lowest category of interleukin-6 and risk of colorectal adenoma. IL-6: Interleukin-6.
Figure 4
Figure 4
Meta-analysis of highest vs lowest category of tumor necrosis factor-alpha and risk of colorectal adenoma. TNF-α: Tumor necrosis factor-alpha.
See this image and copyright information in PMC

Similar articles

See all similar articles

Cited by

See all "Cited by" articles

References

    1. Terzić J, Grivennikov S, Karin E, Karin M. Inflammation and colon cancer. Gastroenterology. 2010;138:2101–2114.e5. - PubMed
    1. Algra AM, Rothwell PM. Effects of regular aspirin on long-term cancer incidence and metastasis: a systematic comparison of evidence from observational studies versus randomised trials. Lancet Oncol. 2012;13:518–527. - PubMed
    1. Itzkowitz SH, Yio X. Inflammation and cancer IV. Colorectal cancer in inflammatory bowel disease: the role of inflammation. Am J Physiol Gastrointest Liver Physiol. 2004;287:G7–G17. - PubMed
    1. Cole BF, Logan RF, Halabi S, Benamouzig R, Sandler RS, Grainge MJ, Chaussade S, Baron JA. Aspirin for the chemoprevention of colorectal adenomas: meta-analysis of the randomized trials. J Natl Cancer Inst. 2009;101:256–266. - PMC - PubMed
    1. Wanders LK, Dekker E, Pullens B, Bassett P, Travis SP, East JE. Cancer risk after resection of polypoid dysplasia in patients with longstanding ulcerative colitis: a meta-analysis. Clin Gastroenterol Hepatol. 2014;12:756–764. - PubMed

Publication types